Selecting Novel Small-Molecule Agents Vs Chemotherapy in KRAS G12C+ NSCLC
February 14th 2024Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Tabelecleucel Yields Benefit in EBV+ Post-Transplant Lymphoproliferative Disease
February 9th 2024The phase 3 ALLELE trial found that using tabelecleucel for patients with relapsed/refractory Epstein-Barr Virus–positive post-transplant lymphoproliferative disease improved efficacy outcomes, specifically for those with hematopoietic stem-cell transplant.